Definium Therapeutics targets three pivotal Phase III readouts in 2026 as enrollment advances and cash runway extends into 2028
Definium Therapeutics, Inc. Common Shares · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · Now $24.06
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS